INTENDED FOR UK HEALTHCARE PROFESSIONALS
Atimos® Formoterol pMDI logo
Background
Atimos® Formoterol pMDI logo with device

Asthma: Licensed in adults and adolescents 12 years and above
COPD: Licensed in adults 18 years and above

Asthma: Licensed in adults and
adolescents 12 years and above
COPD: Licensed in adults 18 years and above

Asthma: Licensed in adults and adolescents 12 years and above
COPD: Licensed in adults 18 years and above

What is Atimos®?

Atimos is available in a pressurised metered-dose inhaler (pMDI), delivering 100 inhalations of 12 micrograms of formoterol fumarate dihydrate per device.

Indications for Atimos1

Asthma
For the long-term symptomatic treatment of persistent, moderate to severe asthma in patients requiring regular bronchodilator therapy in combination with long-term anti-inflammatory therapy (inhaled and/or oral glucocorticoids).

Glucocorticoid therapy should be continued on a regular basis.

COPD
Atimos is indicated for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD).

Atimos® Modulite® pMDI Device
For additional information to share with your patients who have been prescribed Atimos please visit our Atimos patient and carer site.
Reference:
1. Atimos Summary of Product Characteristics. Chiesi Limited.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

Disclaimer

The purpose of this section of the website is to provide UK healthcare professionals with accurate and relevant information on Chiesi Limited respiratory products.

The contents of this area of the website are intended solely for the use of UK healthcare professionals. If you are NOT a UK healthcare professional, please exit this section of the website.

YES I AM

a UK healthcare professional

NO I'M NOT

a UK healthcare professional

UK-RES-1900858 Jun 2019